SHALBY Q2 FY27 CONCALL: TARGETS DOUBLE-DIGIT FY27 HOSPITAL REVENUE GROWTH, EBITDA MARGIN RECOVERY & GURUGRAM CASH BREAKEVEN BY Q4 EXIT; EXPECTS 30–40% MEDTECH COST REDUCTION AND CONTINUED DEBT DECLINE